Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.498
-0.012 (-2.41%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Azitra Revenue
Azitra had revenue of $7.50K in the quarter ending June 30, 2024, a decrease of -95.64%. This brings the company's revenue in the last twelve months to $408.20K, up 12.05% year-over-year. In the year 2023, Azitra had annual revenue of $686.00K with 141.55% growth.
Revenue (ttm)
$408.20K
Revenue Growth
+12.05%
P/S Ratio
0.75
Revenue / Employee
$40,820
Employees
10
Market Cap
3.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 686.00K | 402.00K | 141.55% |
Dec 31, 2022 | 284.00K | 174.00K | 158.18% |
Dec 31, 2021 | 110.00K | -315.00K | -74.12% |
Dec 31, 2020 | 425.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAZTR News
- 2 days ago - Azitra to Present at BIO-Europe 2024 - Business Wire
- 20 days ago - Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Business Wire
- 5 weeks ago - Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
- 6 weeks ago - Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - Business Wire
- 7 weeks ago - Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 2 months ago - Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Business Wire
- 2 months ago - Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Business Wire
- 2 months ago - Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Business Wire